IL13 and Alzheimer disease: Ceramide levels are significantly reduced in the lesional skin of patients with AD, a chronic inflammatory skin disease in which the Th2 cytokines, e.g., IL-4 and IL-13, are key drivers involved with the underlying inflammatory process [16].